Summary
Described here is an immunohistochemical technique using the commercially available monoclonal progesterone receptor (PR) antibody KD 68 in routinely fixed and paraffin-embedded breast carcinomas and lymph node metastases. The authors' technique is compared with several incubation variations. The method applying the primary antibody in a dilution of 1:10 overnight followed by a biotinylated second antibody showed the best results when Triton X-100 was added to the buffer. Using this method, comparison with the results on frozen sections of 34 breast carcinoms yielded a significant concordance of 94%. Correlation between the results on paraffin sections and those obtained by the standard dextran-coated charcoal cytosol assay was 80%. The value of the method for predicting endocrine therapy response was shown in 20 patients. Thus the reliability of the method has been demonstrated and was applied on 151 lymph node metastases and the corresponding primary breast carcinomas from 50 patients. Generally PR content in the metastases was lower than in the primary tumors (p<0.001). This finding indicates that evaluation of PR in lymph node metastases should be included in the decision for endocrine therapy of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 66: 1663–1670, 1990
Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakasz R: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057–7061, 1990
Press MF, Greene GL: Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology 122: 1165–1175, 1988
Elashry-Stowers D, Zava DT, Speers WC, Edwards DP: Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies. Cancer Res 48: 6462–6474, 1988
Anderson J, Orntoft T, Poulsen HS: Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies. Br J Cancer 53: 691–694, 1986
Cheng L, Binder SW, Fu YSet al.: Demonstration of estrogen receptors by monoclonal antibody in formalin-fixed breast tumors. Lab Invest 58: 346–353, 1988
Ciocca DR, Stati AO, Amprino de Castro MM: Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue. Breast Cancer Res Treat 16: 243–251, 1990
De Rosa CM, Ozello L, Greene GL, Habif DV: Immunostaining of estrogen receptor in paraffin sections of breast carcinomas using monoclonal antibody D75P3Gamma: Effects of fixation. Am J Surg Pathol 11: 943–950, 1987
Onetti Muda A, Crescenzi A, Pujia N, Faraggiana T, Marinozzi V: Demonstration of oestrogen and progesterone receptors in freeze-dried, paraffin-embedded sections of breast cancer. Histopathology 18: 511–516, 1991
Shintaku IP, Said JW: Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of breast carcinoma. Am J Clin Pathol 87: 161–167, 1987
Ozzello L, De Rosa C, Habif DV, Greene GL: An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer 67: 455–462, 1991
Perrot-Applanat M, Groyer-Picard MT, Vu Hai MT, Pallud C, Spyratos F, Milgrom E: Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancer. Am J Pathol 135: 457–468, 1989
Scharl A, Vierbuchen M, Conradt B, Moll W, Wurz H, Bolte A: Immunohistochemical detection of progesterone receptor in formalin-fixed and paraffin-embedded breast cancer tissue using a monoclonal antibody. Arch Gynecol Obstet 247: 63–71, 1990
Daxenbichler G, Forsthuber EP, Marth C, Wiegele J, Margreiter R, Müller L, Hausmaninger H, Manfreda D, Dapunt O: Steroid hormone receptors and prognosis in breast cancer. Breast Cancer Res Treat 12: 267–273, 1988
World Health Organization: Handbook for reporting results of cancer treatment. WHO. offset publication No 28, 1979
Sachs L: Angewandte Statistik. Springer Verlag, Berlin, Heidelberg, New York, 1992
Bur ME, Greene GL, Press MF: Estrogen receptor localization in formalin-fixed, paraffin-embedded endometrium and endometriotic tissues. Int J Gynecol Pathol 6: 140–151, 1987
Ballare C, Bravo AI, Sorin I, Guman N, Schiaffi JA, Yomha R, Bagnati A, Lema B, Mordoh J: The expression of progesterone receptors coincides with an arrest of DNA synthesis in human breast cancer. Cancer 67: 1352–1358, 1991
Bevilacqua P, Pea M, Gasparini G: Immunocytochemical detection of progesterone receptor by monoclonal KD-68 antibody in operable breast cancer: correlation with biochemical assay, pathological features and cell proliferative rate. Eur J Cancer Clin Oncol 25: 1595–1602, 1989
Vollmer G, Gerdes J, Knuppen R: Relationship of cystolic estrogen and progesterone receptor content and the growth fraction in human mammary carcinomas. Cancer Res 49: 4011–4014, 1989
Mueller-Holzner E, Zeimet A, Mueller LC, Daxenbichler G, Dapunt O: Monoclonal technique to aid decision on endocrine treatment in breast cancer. Lancet i: 1147–1148, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller-Holzner, E., Zeimet, A.G., Daxenbichler, G. et al. Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases. Breast Cancer Res Tr 25, 47–55 (1993). https://doi.org/10.1007/BF00662400
Issue Date:
DOI: https://doi.org/10.1007/BF00662400